AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (4.1 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

In vivo gene therapy: A strategy for mutations, degenerations, and tumors

Tao Wanga,d, Mingyang Yub,c,d, Ping Liua,d, Zhiqiang Songa, Cheng Lib( ), Jianmin Yanga( ), Na Liua( )
Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai 200433, China
Department of Joint Bone Disease Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
Department of Orthopaedics, The 922nd Hospital of the Joint Service Support Force of the PLA, Hengyang, Hunan 421002, China

Peer review under responsibility of Chongqing Medical University.

d These authors contributed equally to this work.

Show Author Information

Abstract

Gene mutations, organ function degeneration, and carcinogenesis are the primary threats to human health. Gene therapy, which involves the addition, deletion, regulation, and editing of genes, as well as the development of genetic vaccines, can potentially cure genetic mutation disorders, degenerative diseases, and cancers. Ex vivo gene therapy has recently been used to treat monogenetic mutation diseases of the hematopoietic system and cancers. However, in vivo gene therapy remains inapplicable. The primary elements of in vivo gene therapy include deoxyribonucleic acid (DNA) nucleases (e.g., zinc finger nucleases, transcription activator-like effector nucleases), CRISPR-Cas system, base editors, prime editors, and delivery vectors (e.g., viral and non-viral vehicles). According to the development of DNA nucleases and delivery vectors, in vivo gene therapy can be made available for future clinical use. The current review summarizes the development of DNA nucleases and delivery vectors for in vivo gene therapy, emphasizing recent progress.

References

【1】
【1】
 
 
Genes & Diseases

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Wang T, Yu M, Liu P, et al. In vivo gene therapy: A strategy for mutations, degenerations, and tumors. Genes & Diseases, 2026, 13(1). https://doi.org/10.1016/j.gendis.2025.101808

746

Views

6

Downloads

3

Crossref

4

Web of Science

3

Scopus

0

CSCD

Received: 28 August 2024
Revised: 08 December 2024
Accepted: 30 April 2025
Published: 19 August 2025
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).